Gamze Kuser Abali, PhD
Dr. Abali is a postdoctoral fellow of Dr. Cinar. She characterizes the cross-talk between intracellular Hippo (Mst1/2) signaling and prostate cancer progression.
Ahmet Alptekin, MD
Dr. Alptekin is Dr. Cinar’s postdoctoral fellow. He conducts biochemical and molecular analyses of the action of Mst1 on prostate cancer cells.
Ikuko Bentsi-Barnes, PhD
Research Administrative Coordinator
Dr. Bentsi-Barnes is a supporting staff member of the Uro-Oncology Research Program.
Chia-Yi Chu, PhD
Dr. Chu characterized the roles of RANKL-RANK signaling in cancer growth and metastasis. She determines the convergent signaling network between RANK and c-Met that regulates cancer bone colonization.
Bekir Cinar, PhD
Dr. Cinar is an assistant professor of medicine at CSMC and UCLA. He and his colleagues discovered Mst1/Stk4, a Hippo-like serine-threonine kinase, implicated in many cancers, including prostate and lung cancers.
Dennis Jen-Ming Huang, PhD
Dr. Huang is a postdoctoral fellow of medicine at CSMC. Dr. Huang’s research focuses on network analyses of metastatic prostate cancer with focus on molecular mechanisms underlying osteoblastic and osteolytic related gene expression by human prostate cancer cell lines.
Wen-Chin Huang, PhD
Dr. Huang is an assistant professor of medicine at CSMC. Dr. Huang’s research focuses on his new discovery of the roles SREBP1 and SREBP2 play in lipid metabolism and in prostate carcinogenesis.
Sajni Josson, PhD
Dr. Josson studies the role of microRNA in prostate cancer progression. She determines the role of specific oncogenic and tumor suppressive microRNA in the regulation of the tumor-stroma interaction in prostate cancer and in bone metastasis.
Qinlong Li, MD, PhD
Dr. Li is a pathologist who assists with the analysis and interpretation of clinical and experimental cancer specimens and metastatic human prostate cancer models.
Xiangyan Li, MD, PhD
Research Post Doctor
Dr. Li is a postdoctoral fellow of Dr. Wen-Chin Huang. She characterizes the molecular aspects of SREBP action.
Chunyan Liu, BS
Ms. Liu performs CTC isolation, biobanking, and multiplex quantum dot evaluation of clinical specimens.
Srinivas Nandana, PhD
Dr. Nandana is a transgenic mouse expert whose research interest is elucidating T-box transcription factor and RANKL in cancer cell growth, survival, and metastasis.
Changhong Shi, MD, PhD
Dr. Shi is a visiting scientist of medicine. He investigates the molecular mechanisms underlying human prostate cancer metastases with focus on dietary cholesterol and circulating testosterone.
Ruoxiang Wang, MD, PhD
Dr. Wang is an associate professor of medicine at both CSMC and UCLA. He characterizes the stem cell phenotypes in prostate cancer cells, defines the fusion between prostate cancer epithelial and prostate stromal cells, and explores the use of stem cells as therapeutic targeting agent.
Boyang (Jason) Wu, PhD
Dr. Wu discovered an exciting novel therapeutic target, monoamine oxidase inhibitor (MAO), and also characterizes the mechanism of hypoxia regulating MAO expression and near-infrared dye uptake in prostate cancer cells.
Haiyen E. Zhau, PhD
Dr. Zhau is a professor of medicine at CSMC. Her research interest is cancer plasticity and EMT. She developed multiplex imaging technology at the single cell level for cancer prognosis, diagnosis, and treatment follow-up, and for gene expression profiling of CTC in prostate cancer cell models and clinical specimens.
Shabnam Ziaee, BD
Ms. Ziaee’s research focuses on elucidating the roles of androgen receptor and integrins in prostate cancer progression and metastasis.